Isavuconazole Therapy for Nasal-Cerebral Mucormycosis with High Isavuconazole MIC

Area of Science:

• Mycology
• Infectious Diseases
• Clinical Medicine

Background:

• Mucormycosis is a life-threatening fungal infection requiring aggressive treatment.
• Liposomal amphotericin B (L-AMB) is the standard antifungal therapy but can be limited by toxicity.
• Rhinocerebral mucormycosis, particularly in diabetic patients, presents significant management challenges.

Purpose of the Study:

• To report a case of rhinocerebral mucormycosis with brain abscesses refractory to standard therapy.
• To evaluate the efficacy and safety of isavuconazole (ISCZ) in a patient with mucormycosis and high fungal resistance.
• To emphasize the importance of multidisciplinary management in complex fungal infections.

Main Methods:

• A case report detailing the clinical course of a diabetic patient with rhinocerebral mucormycosis.
• Treatment involved initial liposomal amphotericin B (L-AMB) and surgical intervention, followed by a switch to isavuconazole (ISCZ).
• Management included ongoing surgical procedures, optimization of underlying conditions, and long-term ISCZ therapy.

Main Results:

• The patient developed brain abscesses despite L-AMB and surgery.
• Switching to ISCZ resulted in significant clinical and radiological improvement.
• Long-term ISCZ treatment (over one year) was well-tolerated without adverse events, maintaining clinical stability.
• Partial maxillary bone loss was noted during follow-up.
• Clinical improvement occurred despite the fungal isolate showing an ISCZ minimum inhibitory concentration (MIC) >8 μg/mL.

Conclusions:

• Isavuconazole (ISCZ) can be an effective salvage therapy for severe mucormycosis, even in cases with high fungal resistance.
• Multidisciplinary management, including surgical intervention and optimization of comorbidities, is crucial for successful outcomes.
• Long-term treatment with ISCZ appears safe and effective in achieving clinical stability in complex mucormycosis cases.